Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.

Read More »

Urovant Files for IPO to Raise $150 Million

Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.

Read More »

FDA Launches New Pilot Program for Complex Trial Design

The U.S. Food and Drug Administration announced a new pilot program aimed at stimulating the use of complex innovative clinical trial designs for drugs and biologics.

Read More »

PhRMA Releases Annual Survey, Shows Highest R&D Spending Ever

Among the industry group PhRMA’s findings was that overall R&D spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.

Read More »

From “Jeans to Genes”: Dyadic CEO Discusses How To Revolutionize Biopharma Manufacturing

Mark Emalfarb – founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International – believes he knows how to revolutionize biopharma manufacturing.

Read More »

Top 10 Stories of the First Half of 2018

There were plenty of interesting and important stories in the biopharma space during first-half 2018

Read More »

Poietis and Prometheus Team Up To Develop 3D Printing for Bones

Poietis and Prometheus entered into a two-year collaborative research agreement to develop high-precision 3D bioprinting of tissue engineered advanced therapeutic medicinal products for skeletal regeneration.

Read More »

Syneos Health Consulting Releases 10th Annual Biopharmaceutical Dealmakers Survey

The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming more selective in ensuring they have the most appropriate assets and corresponding deals in place.

Read More »

Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint

AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.

Read More »

Recent Hack of Sangamo Therapeutics Exec Underlines Increased Risk for Biopharma

Sangamo Therapeutics recently filed a notice with the U.S. SEC describing a data security breach.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom